Hip fracture
Conditions
Interventions
Control Group:Starting 72 hours before surgery, sham RIPC is administered once daily: An automated tourniquet device is used to perform sham RIPC on one of the patients upper limbs. The tourniquet is
RIPC Group(RG):Starting 72 hours before surgery, Remote Ischemic Preconditioning (RIPC) is administered once daily: An automated tourniquet device is used to perform RIPC on one of the patients upper
Nicorandil Group(NG):Starting 72 hours before surgery, sham RIPC is administered once daily: An automated tourniquet device is used to perform sham RIPC on one of the patients upper limbs. The tourniq
RIPC+Nicorandil Group(RNG):Starting 72 hour
Sponsors
The Seventh Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the relevant inclusion criteria for hip fracture (intertrochanteric fracture or femoral neck fracture) in trauma fracture in the "Guidelines for the Diagnosis and Treatment and Management of Hip Fracture in the Elderly (2022 Edition)", and have an indication for elective surgery; 2. Age>=60 years old, gender is not limited; 3. American Society of Anesthesiologists (ASA) grading assessment level I~III; 4. At least one of the following three risk factors: (1) Previous ischemic heart disease (including angina, myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting); (2) a history of previous stroke; (3) Presence of one of the following 7 cardiovascular risk factors: 1) Age>=70 years; 2) congestive heart failure; 3) a previous transient ischemic attack; 4) Diabetes mellitus and currently taking oral hypoglycemic drugs or insulin; 5) high blood pressure; 6) Preoperative serum creatinine concentration> 175µmol/L; 7) History of smoking within 2 years before surgery.
Exclusion criteria
Exclusion criteria: 1. Patients with high-energy fractures; 2. Patients with bilateral fracture surgery; 3. Patients with pathological fractures; 4. Patients with prosthetic fractures; 5. Peripheral vascular disease; 6. Sulfonylurea hypoglycemic drugs (such as glibenclamide); 7. Combined with severe systemic diseases or insufficiency of important organs, severe arrhythmia; 8. Allergy to local anesthetic drugs; 9. Patients with contraindications to nicorandil; 10. Alcoholism, drug abuse or dependence; 11. Active stage of malignant tumor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| high-sensitivity cardiac troponin I;Blood Urea Nitrogen; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac Troponin I ;Creatine Kinase;Creatine Kinase-MB;N-Terminal Pro-B-Type Natriuretic Peptide;Serum Creatinine;C-Reactive Protein;Tumor Necrosis Factor Alpha;Interleukin-6;Interleukin-1 Beta;Interleukin-10;Tissue Plasminogen Activator;Plasminogen Activator Inhibitor-1;Perioperative incidence of major cardiovascular events;Incidence of perioperative cerebrovascular accidents;Incidence of perioperative delirium;all cause mortality within 30 days of surgery;hospital stays; | — |
Countries
China
Contacts
Public ContactJie Gao;Wenzhi Guo
The Seventh Medical Center of the PLA General Hospital
Outcome results
None listed